Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
A 2025 meta-analysis (a study that pools data from multiple trials to find patterns) confirmed this ranking, with retatrutide showing a mean difference of -16.34 kg vs tirzepatide's -11.82 kg vs placebo (J Endocrine Soc, 2025)
Greenwood-Van Meerveld B
While this risk has not been confirmed in human epidemiological studies, patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) should not use orforglipron or any GLP-1 receptor agonist
Lead to frustration or unsafe weight loss attempts
US$ 28.16
US$ 27.21
.png.jpg)
US$ 23.18
US$ 29.11
US$ 22.42
